APA (7th ed.) Citation

Kasper, B., & Hohenberger, P. (2016). Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib: Translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01). Annals of surgical oncology, 23(6), . https://doi.org/10.1245/s10434-016-5132-4

Chicago Style (17th ed.) Citation

Kasper, Bernd, and Peter Hohenberger. "Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)." Annals of Surgical Oncology 23, no. 6 (2016). https://doi.org/10.1245/s10434-016-5132-4.

MLA (9th ed.) Citation

Kasper, Bernd, and Peter Hohenberger. "Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)." Annals of Surgical Oncology, vol. 23, no. 6, 2016, https://doi.org/10.1245/s10434-016-5132-4.